Breakthrough Innovation in Cancer Care From Merck Pipeline to ...
DARMSTADT, Germany, May 14, 2020 /PRNewswire-AsiaNet/ -- - Results from two studies of BAVENCIO® to be featured in ASCO press briefing- Primary efficacy, biomarker and HRQoL analyses for tepotinib†, the first MET inhibitor to have received a regulatory approval for NSCLC with MET gene alterations
...
Authors: LATEST ASIANET NEWS RELEASES